Does Dr. AMIR ABDI POUR have financial conflicts of interest?

Dr. AMIR ABDI POUR (MD) has received a total of $4,206 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $4,206 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. AMIR ABDI POUR?

According to CMS Open Payments data, Dr. AMIR ABDI POUR received funding from CALLIDITAS THERAPEUTICS US ($2,952), GENZYME CORPORATION ($289), and AURINIA PHARMA U.S ($153).

Does Dr. AMIR ABDI POUR receive research grants or speaking fees?

Dr. AMIR ABDI POUR has received $4,206 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. AMIR ABDI POUR

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: LOMA LINDA, CA 92354

NPI Number: 1912187477

LIFETIME INDUSTRY VALUE

$4,206

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDI POUR is a verified Internal Medicine, Nephrology practitioner based in LOMA LINDA, CA.

Between 2021 and 2024, Dr. ABDI POUR had an overall industry promotional and research financial footprint of $4,206 as recorded in the federal CMS Open Payments database.

$4,206 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDI POUR's primary funding source is CALLIDITAS THERAPEUTICS US, which accounts for $2,952 (representing 70.2% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

CALLIDITAS THERAPEUTICS US

Rank 1

$2,952

70.2%

GENZYME CORPORATION

Rank 2

$289

6.9%

AURINIA PHARMA U.S

Rank 3

$153

3.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.